Eli Lilly and Company (LLY)vsPharming Group NV (PHAR)
LLY
Eli Lilly and Company
$1,354.49
-0.79%
HEALTHCARE · Cap: $1.26T
PHAR
Pharming Group NV
$12.29
-0.08%
HEALTHCARE · Cap: $867.74M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 22256% more annual revenue ($86.46B vs $386.75M). LLY leads profitability with a 31.9% profit margin vs 6.3%. PHAR trades at a lower P/E of 38.3x. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
PHAR
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-32.3%
Fair Value
$11.77
Current Price
$12.29
$0.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Strong operational efficiency at 33.9%
Earnings expanding 74.9% YoY
Reasonable price relative to book value
Revenue surging 20.8% year-over-year
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 30.0x book value
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 3.4% — below average capital efficiency
6.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : PHAR
The strongest argument for PHAR centers on Operating Margin, EPS Growth, Price/Book. Revenue growth of 20.8% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Bear Case : PHAR
The primary concerns for PHAR are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY carries more volatility with a beta of 0.45 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 55/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Pharming Group NV
HEALTHCARE · BIOTECHNOLOGY · USA
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?